ULTRAGENYX PHARMACEUTICAL INC. Shareholders' Equity
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Shareholders' Equity of -$291.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent -$291.00M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$236.00M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$80.00M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $9.16M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$291.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | -$236.00M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | -$80.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $9.16M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $151.00M 10-Q · filed 2026-08-05 | $151.29M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $144.00M 10-Q · filed 2026-08-05 | $144.25M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $255.00M 10-Q · filed 2026-08-05 | $255.30M 10-K · filed 2025-02-19 |
| 2024-09-30 | $346.83M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $432.42M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $140.26M 10-Q · filed 2025-08-06 | |
| 2023-12-31 | $275.00M 10-K · filed 2026-02-18 | $275.41M 10-K · filed 2024-02-21 |
| 2023-09-30 | $31.71M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $129.03M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $220.48M 10-Q · filed 2024-08-02 | |
| 2022-12-31 | $352.00M 10-K · filed 2026-02-18 | $352.49M 10-K · filed 2023-02-17 |
| 2022-09-30 | $468.83M 10-Q · filed 2023-11-03 | |
| 2022-06-30 | $678.07M 10-Q · filed 2023-11-03 | |
| 2022-03-31 | $796.42M 10-Q · filed 2023-08-04 | |
| 2021-12-31 | $922.56M 10-K · filed 2025-02-19 | |
| 2021-09-30 | $933.67M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $972.17M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $1.05B 10-Q · filed 2022-07-29 | |
| 2020-12-31 | $1.15B 10-K · filed 2024-02-21 | |
| 2020-09-30 | $666.19M 10-Q · filed 2021-11-03 | |
| 2020-06-30 | $695.59M 10-Q · filed 2021-11-03 | |
| 2020-03-31 | $609.15M 10-Q · filed 2021-08-03 | |
| 2019-12-31 | $653.76M 10-K · filed 2023-02-17 | |
| 2019-09-30 | $727.26M 10-Q · filed 2020-10-27 | |
| 2019-06-30 | $819.79M 10-Q · filed 2020-10-27 | |
| 2019-03-31 | $886.73M 10-Q · filed 2020-07-30 | |
| 2018-12-31 | $608.91M 10-K · filed 2022-02-15 | |
| 2018-09-30 | $662.60M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $703.97M 10-Q · filed 2019-11-06 | |
| 2018-03-31 | $723.66M 10-Q · filed 2019-08-02 | |
| 2017-12-31 | $383.45M 10-K · filed 2021-02-12 | |
| 2017-09-30 | $365.56M 10-Q · filed 2017-11-03 | |
| 2017-06-30 | $429.45M 10-Q · filed 2017-07-28 | |
| 2017-03-31 | $488.48M 10-Q · filed 2017-05-05 | |
| 2016-12-31 | $473.97M 10-K · filed 2020-02-14 | |
| 2016-09-30 | $455.89M 10-Q · filed 2016-11-08 | |
| 2016-06-30 | $443.89M 10-Q · filed 2016-08-09 | |
| 2016-03-31 | $489.82M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $531.09M 10-K · filed 2019-02-20 | |
| 2015-09-30 | $576.76M 10-Q · filed 2015-11-10 | |
| 2015-06-30 | $319.28M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $341.12M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | $184.94M 10-K · filed 2018-02-21 | |
| 2014-09-30 | $199.33M 10-Q · filed 2014-11-10 | |
| 2014-06-30 | $153.08M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $165.71M 10-Q · filed 2014-05-12 | |
| 2013-12-31 | -$74.82M 10-K · filed 2017-02-17 | |
| 2012-12-31 | -$27.05M 10-K · filed 2016-02-26 | |
| 2011-12-31 | -$7.96M 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |